Shawn Fatholahi
President & Chief Executive Officer MAXONA Pharmaceuticals
Mr. Fatholahi brings more than 20 years of pharmaceutical senior leadership experience to his current role as President & CEO, MAXONA Pharmaceuticals. Prior to founding MAXONA, Mr. Fatholahi was Vice President of Sales and Marketing, for Impax Laboratories, where he built the Impax commercial brand business from the ground up and grew it to more than $245 million in profitable revenues through a combination of organic growth and business development. Mr. Fatholahi has a record of success across a range of therapeutic areas including Central Nervous System (CNS) disorders and has extensive experience in asset identification, integration, product development, and commercialization including launches of blockbuster, specialty, orphan-designated, oral and injectable products.
Seminars
- Reviewing the development of MAX-001, an optimized nefopam formulation designed to deliver rapid onset and extended analgesia without opioids or NSAIDs
- Exploring how preferential norepinephrine reuptake inhibition may modulate pain signalling across acute and chronic pain settings
- Translating Phase 1 safety and pharmacokinetic findings into future clinical development strategies for acute and chronic pain indications
- Positioning triple monoamine reuptake inhibition within the evolving landscape of next-generation non-opioid analgesics
